Lotus Pharmaceutical Co., Ltd. (TWSE: 1795)
Health Care · Pharmaceuticals · TW
NT$196.50
+8.86% today · +1.6% 1Y
Lotus Pharmaceutical Co., Ltd. (TWSE: 1795) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.64B and employs 1,099 people.
Over the last twelve months the share price has gained 1.6%, trading between 170.50 and 369.50.
Tweenvest scores Lotus Pharmaceutical Co., Ltd. across four factors: quality 74/100, value 78/100, growth 85/100, dividend 57/100. Its strongest factor is growth.
1795 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.64B
- Revenue (TTM)
- $895.36M
- P/E
- 13.64
- EPS
- 14.41
- Dividend yield
- 1.30%
- Beta (5Y)
- 0.64
- 52-week high
- NT$369.50
- 52-week low
- NT$170.50
- Avg volume (3M)
- —
- Shares outstanding
- 266.23M
- Employees
- 1,099
- Next earnings
- —
About Lotus Pharmaceutical Co., Ltd.
Lotus Pharmaceutical Co., Ltd. operates as a pharmaceutical enterprise, specializing in the research, development, production, and sale of generic medicines. Its market presence extends across Taiwan, South Korea, the United States, and other global territories. The company primarily targets therapeutic areas such as oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system conditions with its generic product line. In addition to prescription generics, Lotus also offers a diverse array of over-the-counter drugs. Diversifying its business activities, the firm engages in the wholesale distribution of cosmetics, the retail of specialized clinical equipment, and provides biotechnology consulting. It also handles the sale of pharmaceuticals and medicinal chemicals, conducts marketing campaigns, offers market planning and business intelligence services, and provides advisory on health management and health technology. Furthermore, Lotus delivers a suite of services including project management for pharmaceutical regulatory compliance, data collection, and agency functions. It also operates as a healthcare consultancy and a Contract Research Organization (CRO). Established in 1966, Lotus Pharmaceutical Co., Ltd. maintains its principal office in Taipei City, Taiwan. The company is a subsidiary of Alvogen Emerging Markets Holdings Limited.
- ISIN
- TW0001795003
- Founded
- 1966
- Listed since
- Dec 21, 2007
- Exchange
- Taiwan Stock Exchange
- Currency
- TWD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,191.00 | -3.46% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.22 | -1.07% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.31 | -0.91% |
Figures last refreshed Aug 18, 2026.